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Summary Pretargeting techniques using the avidin-biotin system have shown encouraging results in both diagnostic and therapeutic clinical
trials. It has been shown that in cancer therapy the ideal agent to be used for pretargeting should have a plasma half-life longer than avidin
and lower immunogenicity than streptavidin in order for these procedures to be applied safely and repeatedly in patients. We prepared a
recombinant form of avidin with no carbohydrates and avidins, biochemically modified either by decreasing the positive charges with succinic
anhydride or by linking polyethylene glycol (PEG) at three different molar ratios and evaluated their in vivo behaviour after i.p. administration
in mice. The succinylation and PEGylation of avidin increased the plasma half-life proportionally to the degree of protein modification. The
procedures, however, affected the biotin binding to some extent. The biodistribution studies showed that, for all six time points (ranging from
20 min to 18 h post-injection), the liver and kidney to blood ratios were lower for PEGylated avidins than native, recombinant and succinyl
avidin. Recombinant and low PEGylated avidin evoked an immune response in all mice after at least three injections. Native, recombinant
and succinyl avidins showed higher serum titres than PEGylated avidins. In conclusion, the conjugation of avidin to PEG chains (n = 7)
originates a compound with a suitable blood clearance, low immunogenicity and concurrent low cross-reactivity with avidin.
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Avidin (AV) and streptavidin (SA) have a similar tetrameric
protein conformation and affinity for biotin (Kd = 10- M), but
differ in primary amino acids sequence, net charge, glycosylation
and immunocross-reactivity (Green, 1975). Avidin contains twice
the number of the basic amino acids lysine and arginine than SA;
therefore, the isoelectric point of AV is approximately 10
compared with about 7.0 for SA. Approximately 10% of avidin's
mass is due to heterogeneous oligosaccharides, largely composed
of mannose and N-acetylglucosamine (DeLange, 1970; Bruch and
White, 1982). Because of their high affinity for biotin, they have
been used in numerous biotechnological applications (Wilchek
and Bayer, 1988, 1989) and in different in vivo procedures such as
radioimmunodetection and drug immunotargeting (Hnatowich et
al, 1987; Paganelli et al, 1990, 1995). Radiolabelled AV and SA
show different plasma pharmacokinetics and in vivo behaviours
(Rosebrough, 1993; Sung et al, 1994; Grana et al, 1996). Avidin is
quickly cleared from circulation via the reticuloendothelial system
and its clinical utility as a clearing agent 'chase' for biotinylated
monoclonal antibodies (MAbs) has been proved (Kobayashi et al,
1994; Paganelli et al, 1994).
Multistep approaches have evolved and encouraging results
have been obtained in animal models (Alvarez-Diez et al, 1996)
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and in b'oth diagnostic and therapeutic clinical trials (Paganelli et
al, 1996; Samuel et al, 1996). Efforts are under way to improve the
system through the optimization of each component including the
nature of the MAb-streptavidin conjugate, the clearing agent
and the radiolabelled biotin derivative (Axworthy et al, 1995;
Beaumier et al, 1995). A pretargeting protocol, applied to radio-
immunotherapy of brain tumours, involves the combined use of
AV and SA in the second step (Paganelli et al, 1996). In this
method, AV is injected first to remove circulating biotinylated
MAbs forming complexes that are efficiently removed by the liver
chase effect' (Paganelli et al, 1994). Then, SA is slowly infused
with the purpose of obtaining a better 'avidination' of the tumour
than AV as a result of its longer residence time in blood. Although
the system has been optimized and has shown objective clinical
responses (Paganelli et al, 1997a), the relevant immune response
to these xenoproteins, especially SA (Paganelli et al, 1997b),
considerably limits the procedure. In an effort to replace the highly
immunogenic SA and prolong the presence in the circulation of
AV, we focused on AV and prepared a recombinant form with
no carbohydrates. We also biochemically modified AV in two
ways: (a) by neutralizing its lysine residues with succinic anhy-
dride; and (b) by covalently linking PEG via its amino groups
at different molar ratios. The pharmacokinetics, biodistribution
and immunogenicity of recombinant and modified AVs were
investigated in immunocompetent mice in comparison with native
AV and SA.
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MATERIALS AND METHODS
Avidin and streptavidin
Both products were purchased from Societa Prodotti Antibiotici
(Milan, Italy). Native avidin from pure egg white was purified
according to a previously described procedure (Green, 1970).
Streptavidin, produced from Streptomvces avidinii, was isolated
from fermentation filtrates following a purification method that
included ion exchange and affinity chromatography, ultrafiltration
and lyophilization. Overall the procedure yielded a highly purified
SA without buffer salts.
Preparation of recombinant avidin (rec-AV)
A synthetic cDNA encoding for the full and correct sequence of
hen avidin was cloned into an Escherichia coli expression vector.
The insoluble avidin expressed by the transformed bacteria was
solubilized, renatured and purified by affinity chromatography on
an agarose iminobiotin column (Sigma, St Louis, MO, USA) to
obtain pure and functional rec-AV at levels of about 20 mg 1-1 of
cell culture. Electrophoretic and size exclusion chromatography
experiments showed the protein to be pure, to have a tetrameric
structure and to lack a carbohydrate moiety. The biotin-binding
capacity was shown to be similar to that of the natural protein.
Before the in vivo experiments, the preparation of pure rec-AV
was repeatedly passed through detoxy gel (Pierce, Rockford, IL,
USA) to reduce the endotoxin concentration to 15 EU mg-' of
protein. Details on rec-AV cloning, expression, purification and
characterization are described elsewhere (Shin et al, 1997).
Preparation of modified avidins
Succinyl avidin (suc-AV)
Avidin was reacted with succinic anhydride to obtain a totally
modified N-acylderivative product using a molar ratio succinic
anhydride-avidin of 136. The electrophoretic properties ofsuc-AV
were examined by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) according to previously described
procedures (Laemmli, 1970). The isoelectric point (pl) was deter-
mined by isoelectric focusing (PhastSystem, Pharmacia, Uppsala,
Sweden) applying in parallel to suc-AV pl standards (Pharmacia).
The biotin-binding activities were determined using the dye 4-
hydroxyazobenzene-2'-carboxilic acid (HABA), which binds only
to avidin and is displaced by biotin (Green, 1970).
Avidin-mPEG conjugates
Monomethoxypolyethyleneglycol 5000 (Sigma) (mPEG) was
functionalized by norleucine (Nle) and activated at the
aminoacidic carboxylic group as succinimidyl ester to obtain
mPEG-Nle-OSu (Sartore et al, 1991). Proper amounts of the
activated oligomer were added to AV solutions in 0.1 M borate
buffer pH 8.0 (10 mg ml-') in order to reach protein NH,/polymer
ratios of 1:0.2, 1:0.3 and 1: 1.
The samples were maintained for 30 min at room temperature
under stirring and purified by gel filtration chromatography using
a Superose 12 analytical column (Pharmacia) eluted by 10 mM
phosphate buffer, 0.15 M sodium chloride pH 7.2.
The eluted fractions were analysed by optical density (OD) at
280 nm for protein detection and by iodine test for polymer (Sims
and Snape, 1980). The elution volume, corresponding to the
avidin-mPEG conjugate, was collected and concentrated by ultra-
filtration using an Amicon system with a PM 10 membrane (cut-
off 10 000).
The protein concentration was evaluated by the biuret method
(Gornall et al, 1949) and amino acid analysis, whereas the degree
of avidin modification (percentage of derived protein amino
groups) and the average number of mPEG chains covalently
linked per AV molecule were determined by amino acid analysis
on the basis of the Nle content as reported in the literature
(Bidligmeyer et al, 1984).
Enzyme-linked immunosorbent assay (ELISA) to test
biotin binding in vitro
Biotin binding of mPEG avidins was checked using an ELISA
system. Solutions of avidin and mPEG avidins in 0.1 M bicar-
bonate buffer pH 9.5, preventively analysed by fast protein liquid
chromatography (FPLC System, Pharmacia) equipped with a gel
filtration column (Superdex 200, Pharmacia) were serially diluted
in a range of5-0.01 ,ug ml-' and samples of 100 ,ul were incubated
overnight at 4°C in 96-well plates for coating. After incubation the
wells were washed three times with 250 gl of 10 mM phosphate
buffer, 0.15 M sodium chloride pH 7.2 and Tween 20 (0.3%).
The wells were incubated with 200 pl of 50 gg ml-' bovine
serum albumin (BSA) in 0.05 M Tris-HCl, 2 mM EDTA, 0.3 M KCI
pH 8 for 1 h at 37°C, washed as above and incubated with 100 ,l
of biotin-rat IgG conjugates (Sigma) diluted 1:500 in phosphate-
buffered saline (PBS)/Tween pH 7.2 for 1 h at 37°C. The wells
were further washed and incubated with 100 .tl of rabbit alkaline
phosphatase anti-rat IgG conjugates (Sigma) diluted 1:10000 in
PBS/Tween pH 7.2 for 1 h at 37°C. The plates were washed
five times and finally 100pl of substrate solution (Sigma-104,
1 mg ml-' in 1 M diethanolamine, 0.5 mM MgCI, pH 9.8) was
added. The enzymatic reaction was stopped after 1 h by addition
of 50 pl of 3.0 N NaOH and the OD at 405 nm read on a 96-well
plate reader (AutoReader II, Ortho). The residual binding ofmodi-
fied avidins for biotinylated antibodies was estimated as per cent
of the value obtained with native avidin as follows:
(dilution of mPEG AVs giving an OD reading of0.3)
Xl 00 (dilution of native AV giving an OD reading of0.3)
An absorbance value of0.3 was chosen because it corresponded to
three times the background.
Radiolabelling
Avidin, SA and the modified avidins were radiolabelled with 1251
using the chloramine-T method (Hunter and Greenwood, 1962).
Briefly, 0.5 mg of protein in 0.5 ml of 0.5 M phosphate buffer (pH
7.5) and 50,tl of aqueous solution of chloramine-T (10 mg ml-')
(Sigma) were added to a 1.5-ml Eppendorf containing radioiodine
diluted with 0.05 M sodium hydroxide. The reaction was quenched
after 5 min with 100 tl of 5% sodium metabisulphite. The radio-
iodinated protein was separated from free iodine by PD-1Ogel
chromatography (Sephadex G-25, Pharmacia). As previously
reported (Rosebrough, 1993), the labelling efficiency of SA was
much higher than that of AV.
Therefore, SA was radiolabelled with starting activities ofapprox-
imately 11 MBq of 1251 and the other proteins with approximately
37 MBq of 1251.
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Figure 1 Biodistribution of 1251-labelled AV ( ), rec-AV (U), suc-AV (U), SA (E), AV-mPEG-3 (3) and AV-mPEG-7 (C:) after a single intraperitoneal injection.
A 30 min. B 2 h. C 4 h. Data are expressed as the per cent of the injected dose per milligram of tissue (% ID mg-'). Vertical bars indicate s.d. (n = three mice per
point)
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In vivo pharmacokinetics and biodistribution
Experiments were performed on 6-week-old female Balb/c mice
(Charles River) housed and maintained under sterile conditions
and receiving autoclaved food and water. Animal treatments were
performed according to institutional and European guidelines.
Mice received a Lugol solution (0.02% I,) and KCIO4 in their
drinking water for 3 days before radiolabelled protein administra-
tion and throughout the experiments to block free iodine uptake
by the thyroid gland and the stomach mucosa. Groups of three
animals per time point received an i.p. injection of 10-20 tg ofthe
radioiodinated proteins and were sacrificed at 30 min, 1, 2, 4,
6 and 18 h post-injection. Major tissues (blood, liver, spleen,
kidneys, lungs and bone) and urine were obtained, weighed and
counted in a gamma counter. The biodistribution data were
calculated as percentage injected dose per milligram of tissue
(% ID mg-') and represented the mean values of three mice per
time point (Figure 1).
To establish the pharmacokinetics, the blood samples were
weighed and counted in a gamma counter. Then, after centrifuga-
tion, the serum separated and trichloroacetic acid (TCA) 20% was
added to each sample. The precipitate was then separated from the
supernatant and both portions counted separately in the gamma
counter. The percentage of the total activity recovered in the
precipitate (%TCA) was used in the calculation of the pharmaco-
kinetic profiles. The plasma clearance curves were obtained using
fitting program software (SAAM II, University of Seattle, WA,
USA) plotting versus time the %ID mg-' calculated as follows:
(c.p.m. mg-') x (%TCA)
%ID mg-' =
(c.p.m.)
where c.p.m. mg-' is the ratio between the total activity of the
blood samples and their weight and c.p.m. is the activity of the
administered dose.
Immunogenicity studies
The effect of different manipulations on the immunogenicity of
avidin was tested in female Balb/c mice. For each modified avidin
as well as native avidin, groups of 5-6 animals were injected i.p.
and s.c. with 20-40 gg total of protein on days 0, 10, 16 and 51.
For all the injections, the same preparation of each protein was
used. The solutions were stored at 4°C and their stability tested by
fast protein liquid chromatography before to injection. Blood
samples were drawn from the retro-orbital sinus before the experi-
ment and on days 10, 16, 23 and 76 after the first administration.
The sera were collected by centrifugation and were tested for anti-
avidin reactivity using an ELISA.
ELISA to test for antibodies to modified avidins
Microtitre wells (Falcon 3912, Becton Dickinson) were precoated
with human biotinylated albumin at 10 tg ml in 0.05 M
carbonate buffer, pH 9.6 for 90 min at 37°C (50 ,ul per well) to
block the AV, rec-AV and the modified avidins on the plates,
because the direct coating was not applicable to all samples. The
plates were then washed three times with PBS/0.05% Tween 20
and coated with each modified avidin at 10 tg ml in PBS/Tween
for 60 min at 37°C. This concentration had previously proved to
be sufficient for saturating all biotin-binding sites ofthe precoated
albumin. After three washes with PBS/Tween, the non-specific
binding sites on the plastic were saturated with I % standard
defatted milk in PBS/Tween for 60 min at 37°C and the plates
were again washed three times with PBS/Tween. Then, dilutions
of the serum samples, of 1:25 and 1:100, and of a mouse mono-
clonal anti-avidin antibody standard (mouse ascites fluid, Sigma)
from 1:200, were added to the wells for 60 min at 37°C (50 gl per
well), washed eight times with PBS/Tween and finally a 1:2500
dilution of peroxidase-linked goat anti-mouse-Ig (Sigma) was
Table 1 Characteristics of mPEG-modified avidins
Protein amino Degree of Polymer chains bound to
groups per polymer modification (%)a avidin (mean value)a
AV-mPEG-3 1:0.2 7.5 3
AV-mPEG-7 1:0.3 17.5 7
AV-mPEG-15 1:1 37.5 15
aDetermined by Nle content (Bidligmeyer et al, 1984).
Table 2 Molecular properties of AV, SA, rec-AV and modified AVs
Mol. wt. plb Biotin binding
average value % increaseda (%M
AV 66 000 - 9-10 100
SA 60 000 - 6-7 100
rec-AV 63000 - 9-10 100
suc-AV 67 000 - 3.5-3.7 50
AV-mPEG-3 80 000 21 9-10 50
AV-mPEG-7 91 000 38 5-6 33
AV-mPEG-15 132 000 100 ND 10
aDetermined by electrophoresis for rec-AV and suc-AV; theoretical values for mPEG avidins; see Green (1975) for AV and Chaiet and Wolf (1964) for SA.
bDetermined by isoelectric focusing. cDetermined by the ELISA system for mPEG avidins and by HABA method for the other proteins (see Materials and
methods).
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added for 45 min at 37°C. The wells were washed again eight
times and the assay was then developed with o-phenylenediamine
dihydrochloride (OPD, Sigma), blocked after 30 min of chromo-
genic reaction with 10% sulphuric acid and the OD at 490 nm read
using an ELISA plate reader (AutoReader II, Ortho). The sera with
an OD three times higher than the background (0.080) were
considered as positive antibody reaction. On them, we repeated an
ELISA test similar to the one previously described, in which
dilutions of positive mouse serum from 1:25 and of a mouse
monoclonal anti-avidin antibody standard were incubated. We
calculated the reciprocal value ofeach serum titre giving an OD of
three times the background and the immunogenicity of each
modified avidin was compared with that of a native AV.
RESULTS
Biochemical and functional characteristics
The composition of avidin-mPEG conjugates obtained using
different protein amino groups-polymer molar ratios in the prepa-
ration are reported in Table 1.
The degree of modification (percentage of derivatized protein
amino groups) was not linear with the increase in mPEG added to
the reaction, thus the number of polymer chains bound to avidin
ranged from 3 to 15.
After modification, the proteins changed their molecular weight,
isoelectric point and in vitro biotin-binding affinity (Table 2).
In the case ofmPEG avidins, although the method adopted for AV
modification enabled a quite accurate determination of the number
ofbound PEG molecules, the molecular weights reported in Table 2
are theoretical values as the mPEG reagent is made up of different
molecular weight molecules (average mol. wt. = 5000 Da).
The average molecular weight increase was quite irrelevant for
suc-AV, whereas it was evident (21%, 38% and 100%) for mPEG
avidins.
The modification ofthe net charges ofthe molecules was partic-
ularly evident by succinylation of AV, with the pl decreasing from
the 9-10 of native AV to the 3.5-3.75 of suc-AV. Rec-AV and AV-
mPEG-3 presented, by isoelectric focusing, substantially the same
pl as native AV, whereas AV-mPEG-7 showed a band corre-
sponding to a pl of5-6.
The ELISA system was used to estimate the biotin binding of
mPEG avidins as it was considered suitable and reliable. In fact,
previous studies had demonstrated that mPEG chains did not affect
the coating of avidin to the wells (Veronese et al, 1996).
The biotin binding ofAV substantially decreased after biochem-
ical modifications, as reported in Table 2. Only rec-AV maintained
the same recognition ability as native AV and SA, whereas, by
increasing the number of mPEG chains on the protein surface, the
percentage of biotin binding progressively decreased to reach a
minimum value of 10% with AV-mPEG-15.
Pharmacokinetics and tissue distribution
SA, AV and its derivatives were radiolabelled with 1251 and injected
i.p. into normal mice (ni = 3 per time point, per protein) to investigate
in vivo the effect of the protein modifications. The labelling effi-
ciency ranged from 20% to 25% for native AV and the other modi-
fied avidins, whereas for native SA it was approximately 80%.
The in vivo stability of the radiolabelled proteins was deter-
mined by TCA precipitation on the blood samples obtained at the
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Figure 2 Anti-avidin response in individual mice after injection of AV, rec-AV
and modified avidins determined by ELISA. Results are expressed as the
reciprocal value of each serum titre giving an OD (at 490 nm) of three times
the background. O, Results after 23 days; *, results after 76 days; -, mean
value
time of sacrifice. The results indicated that only 5-25% of free "25I
was present in circulation up to 18 h post injection, with the excep-
tion of AV-mPEG-3 and rec-AV, in which the release of radio-
activity was particularly significant (90% and 64% respectively).
The plasma clearance curves ofAV, SA and modified avidins were
calculated. The best biexponential fitting was determined for each
experimental curve and the correlation coefficient, calculated on
the mean values, was found to be elevated for all, ranging from
0.920 to 0.997. The first rising portion of the curves probably
represented the absorption of the radiolabelled proteins from the
peritoneal cavity into the circulation. The fast phase ofelimination
was very rapid, and it was not possible to make any comparison
between the various half-lives (t1/2a)' whereas for the slower elim-
ination phase t1,2 values were obtained.
['25I]rec-AV cleared from circulation more rapidly than native
AV (t1/20 =0.8 vs 1.3 h).
[I251]suc-AV and ['251]AV-mPEG-3 cleared more slowly than
native AV, but still exhibited relatively rapid clearance (t,,,2 = 2.2
and 2.6 h respectively). The blood clearance of [125I]AV-mPEG-7
was substantially prolonged with a half-life calculated for the
beta component of the curve of 5.8 h approaching that of [T25I]SA
(t,,2f =8.9 h).
The high degree of modification (38%) of AV-mPEG- 15
extended its plasma half-life beyond that of SA (t,,,12 = 12 h). In
light of this observation, in addition to the disappearance of the
capacity of biotin binding, this modified avidin was not further
investigated in the biodistribution studies.
The results of the biodistribution studies, obtained at 30 min,
2 and 4 h post injection, are presented in Figure 1 as %ID mg-'. SA
showed the highest accumulation in kidneys and blood, at 2 and 4 h
post injection, compared with all the other proteins. As expected,
AV presented an initial high uptake in blood (0.0223 ± 0.0168%ID
mg- at 30 min) followed by a rapid disappearance (0.0048 ± 0.0002
at 2 h and 0.0027 ± 0.0016 at 4 h). Liver uptake was rather high for
AV, SA and suc-AV at 30 min (0.0088 ± 0.0024; 0.0069 + 0.0026
and 0.0074 ± 0.0034 respectively) and 2 h post injection (0.0196 ±
0.0065; 0.0084 ± 0.0014 and 0.008 ± 0.0032 respectively). At 4 h,
liver uptake of SA increased drastically (0.0534 + 0.0304), whereas
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AV and suc-AV showed a moderate decrease (0.013 + 0.0048
and 0.0032 ± 0.001 respectively). Rec-AV and suc-AV presented
an initial moderate uptake in blood (0.031 ± 0.0007 and
0.0068 ± 0.0041 respectively at 30 min) that decreased progres-
sively with time (0.0024 ± 0.0012 and 0.0019 ± 0.0002 respectively
at 4 h). Except forthe high accumulation in kidneys at 2 and4 h post
injection (0.0596 + 0.0031 at 2 h and 0.0317 ± 0.0062 at 4 h), no
other target organ was evident for rec-AV. Suc-AV, instead, showed
low accumulation in kidneys (0.008 ± 0.0005 at 4 h) but the highest
spleen uptake at 2 h (0.0123 ± 0.0112).
The two mPEG avidins showed a different behaviour in blood.
The radioactivity associated with AV-mPEG-3 remained constant
from 30 min to 2 h post injection and then decreased at 4 h (0.005 ±
0.0011 at 30 min and 0.0028 ± 0.0003 at 4 h). However, AV-mPEG-
7 presented a progressive increase up to 4 h post injection (0.0036 +
0.0006 at 30 min; 0.0072 ± 0.0008 at 2 h; 0.0106 ± 0.0086 at 4 h)
and then subsequently declined (data not shown). Kidney and liver
uptake of the mPEG avidins was lower at 2 and 4 h post injection
than uptake of all the other proteins. The liver and spleen uptake of
AV-mPEG-7 at 30 min post injection was the lowest of all the
proteins (0.0027 ± 0.0014 for liver and 0.003 ± 0.00014 for spleen).
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Immunogenicity studies
In order to evaluate immunogenicity (Figure 2), mice were
injected i.p. and s.c. with modified AVs. Antibody response
against the homologous immunogen, evaluated by ELISA, became
detectable in the majority of tested animals after two (rec-AV and
AV-mPEG-3) or three injections (AV and suc-AV) and rose to a
high titre after a further boost at day 51. All animals survived the
completion of the experiment without any evidence of alteration
of their vital signs. A high inter-animal variability in the level of
antibody response was observed. Immunization with AV-mPEG-7
resulted in a positive response in only one mouse out of six after
the third boost injection. On the other hand, AV-mPEG-3, suc-AV
and rec-AV elicited an almost complete response after the third
boost injection. Even after the last injection, the titre of binding
activity of the serum of mice immunized with AV-mPEG-7 and
AV-mPEG-15 was low compared with that of anti-AV sera.
Sera of animals immunized against each modified AV and posi-
tive at the last bleeding were pooled and their binding reactivity
was evaluated on microtitre plates coated with native AV. The sera
anti-rec-AV, -suc-AV and -AV-mPEG-3 showed an evident but low
cross-reactivity (between 20% and 30%), whereas AV-mPEG-7-
and AV-mPEG-15-induced responses appeared not to recognize
native AV.
The cross-reactivity of modified vs native AV was also evalu-
ated by testing the reactivity of the pooled antinative AV sera
(Figure 3A) and of an anti-AV monoclonal antibody (Figure 3B)
on microtitre plates coated with the different modified AVs. To
take into account the different coating ability after AV modifica-
tion, the amount of the various preparations was increased up to
the saturation of biotin binding. Under these experimental condi-
tions both polyclonal (data not shown) and monoclonal binding
titration curves reached a plateau (Figure 3B). The recombinant
form was recognized as the native molecule, whereas, after PEG
modification, AV was detected, to a lesser extent, in a dose-
dependent manner (from 15% to 70%) by both polyclonal and
monoclonal sera.
The Scatchard analysis of the monoclonal antibody-binding
data indicated that, by increasing the mPEG substitutions, the
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Figure 3 Evaluation of the residual antigenicity of AV after modifications
determined by ELISA coating with the different modified avidins: AV (U), rec-
AV (0), suc-AV (*), AV-mPEG-3 (0), AV-mPEG-7 (A) and AV-mPEG-15 (0).
Reactivity of the pooled antinative AV sera (A) and of an antinative AV
monoclonal antibody (B)
number of recognized antigenic sites progressively decreased
down to about 40% in AV-mPEG-15 relative to native AV. Suc-AV
was detected at an intermediate level by both polyclonal and
monoclonal anti-AV response.
DISCUSSION
Pretargeting techniques have been shown to reduce normal tissue
toxicity, especially to the bone marrow, which has been the major
limiting factor in the application of radioimmunotherapy to solid
tumours. Among the variety ofcombinations between targeting and
effector molecules (Goodwin, 1995), the avidin-biotin system has
certainly been the most studied in the clinical setting (Fazio and
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Paganelli, 1993). Recent studies have also shown that avidin is
effective as a 'chase' to clear biotinylated antibodies from circula-
tion (Paganelli et al, 1994). However, in the three-step approach,
because of its fast half-life, it is unlikely that high levels of AV can
be targeted on to the tumour (Magnani et al, 1996). Conversely, the
longer half-life and higher tissue retention of streptavidin (Schechter
et al, 1990; Grana et al, 1996) can convey more SA and so more
radiolabelled biotin on to the tumour. Therefore, streptavidin has
been preferred to AV in therapy trials (Paganelli et al, 1996).
However, the major drawback of this system lies in the immuno-
genicity of this xenoprotein (Paganelli et al, 1997b) and therefore an
investigation aimed at identifying a reagent with longer plasma half-
life than AV and lower immunogenicity than SA was undertaken.
The use of a modified avidin with such characteristics may
represent a step forward in the management of cancer patients, as
repeated cycles of therapy could be foreseen.
PEG is a linear, water-soluble, uncharged, flexible polymer that
is available in various molecular weights and can be readily acti-
vated to allow for coupling to proteins (Delgado et al, 1992). In
this investigation, we used the monomethoxy end capped (mPEG)
of 5000 Da and the conjugation was performed at three different
molar ratios as it has been reported that the plasma half-life of
mPEG-proteins is prolonged by increasing the number of mPEG
chains. Reduction of the cationic charge of AV by neutralization of
its lysine residues with succinic anhydride or other anhydrides
(Kang et al, 1995) has been indicated as a means of decreasing the
liver localization of AV and of prolonging the plasma half-life
(Rosebrough et al, 1996). Recent progress in the cloning of avidin
cDNA into an E. coli expression vector has made it possible to
produce large amounts of a pure recombinant avidin lacking the
carbohydrate moiety and with an affinity for biotin similar to the
natural protein (Shin et al, 1997).
Loss of bioactivity after chemical modifications has frequently
been noted for several enzymes and hormones. PEG-coupled anti-
bodies have recently shown improved tumour localization but it
was accompanied by a reduction in antigen binding (Delgado et al,
1996). This also occurred in avidins, as increasing the number
of mPEG chains bound per molecule of AV also progressively
decreased the in vitro biotin binding evaluated by an ELISA assay.
At present, it is difficult to explain the reason for this decrease in
binding as the mPEG has been coupled to AV through the NH,
groups of lysine residues. Other amino acids, such as tyrosine,
have been demonstrated to be more important for biotin binding
than lysine. In fact, it has been reported that the modification of
two tyrosine residues per AV tetramer was sufficient to abolish
completely the biotin binding (Gitlin et al, 1990).
It has also been suggested that the flexible long chain of the
mPEG polymers sterically interferes with the substrate approach to
the active binding site (Marshall et al, 1996). In this study, a high
molecular weight polymer was used and that may explain the loss
of 50% in the biotin binding observed with only an average of
three polymer chains linked to AV. In fact, conjugation to SA of
small molecules such as galactose with molar ratios galactose-to-
SA of 10 and 25 exhibited no reduction in the biotin binding
(Rosebrough and Hartley, 1996).
The observed extension of the plasma half-life by increasing
the mPEG modification of AV has been previously reported
(Kamisaki et al, 1981) and discussed (Marshall et al, 1996). mPEG
modification is supposed to provide a protection as a surface
barrier to large molecule interaction such as proteolytic enzymes,
thus making clearance slower as has already been reported for
several proteins (Nucci et al, 1991; Kartre, 1993). The modifica-
tion with an average of seven mPEG chains appeared to be ideal to
raise the plasma clearance of AV to a value (5.8 h) intermediate
between those of AV and SA. However, the plasma clearance of
AV was not significantly prolonged by the modification with
succinic anhydride as the plasma half-life of suc-AV (2.2 h) was
only slightly longer than that of AV (1.3 h) as previously reported
by others (Kang et al, 1995). The high clearance pattern of rec-AV
(0.8 h), even shorter than that of AV, is not totally surprising. It has
been reported that a commercial product, called NeutraLite avidin
(Eurogentec, Belgium), in which all the carbohydrate moieties of
the glycoprotein have been removed and the isoelectric point has
been lowered to neutral, showed in rats a slow plasma clearance
similar to SA. In addition, in the same animal model, another
modified avidin, only partially (50%) deglycosylated, showed
instead a fast clearance similar to AV. The study concluded that the
plasma clearance of modified avidins was largely influenced by
the combination of the degree of glycosylation and the charge of
the avidin analogue (Kang et al, 1995).
Biodistribution studies were performed in mice after labelling
the proteins with 1251. For uniformity, the chloramine-T method
was adopted for all proteins and the amount of protein adminis-
tered was maintained constant. On the other hand, the
Bolton-Hunter reagent, recommended especially for proteins with
low tyrosine content such as AV (Schechter et al, 1990), reacts
with primary amines that have been derived in the preparation of
PEG AVs and suc-AV.
The long physical half-life of 1251 suggested that the i.p. route of
administration could be used instead of the i.v. injection in the
comparison among the different modified avidins (Hnatowich et
al, 1987). It was found that approximately 25% of 1251 avidin accu-
mulated in the liver at 2 h and that the uptake decreased with time
(approximately 5% at 18 h). High liver uptake (approximately
50%) has been reported 2 h after the i.v. injection of radioiodinated
AV in rabbits (Rosebrough and Hartley, 1996) and the mannose
receptor binding, most probably present in the liver Kupffer cells,
was indicated to be the cause of such high accumulation. In this
investigation, we observed that the mPEG modification prevented
the mannose receptor binding as AV-mPEG-3 and AV-mPEG-7
showed at 2 h liver uptake lower than that of rec-AV, which lacks
the carbohydrate moiety. The observation that AV and other
cationic proteins accumulated in vitro and in vivo on the
glomerular membrane (Border et al, 1982; Kaseda et al, 1985) was
confirmed in this study because at 2 h post-injection AV kidney
uptake was about 12% whereas, on the other hand, suc-AV and
AV-mPEG-7 showed < 1% accumulation.
The immune response evoked by PEGylated AV was weaker and
delayed compared with that induced by native AV. Analysis of the
binding data of monoclonal and polyclonal sera antinative AV
suggests that the PEGylation may mask antigenic sites on the mole-
cule. However, we cannot exclude that a modification of AV anti-
genic portions could also take place and contribute to the total
antigenicity. These results are in agreement with those obtained in
the PEGylation ofgalactosylated streptavidin (Marshall et al, 1996).
Rec-AV and suc-AV elicited an immune response comparable in
intensity and time of development to that of native AV, although
suc-AV showed only a partial cross-reactivity with native
molecule, suggesting that this type of modification could alter its
antigenic pattern.
The low cross-reactivity of some modified avidins with native
AV may have an important impact for future clinical applications of
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these molecules as it could be feasible to administer safely modi-
fied avidins in patients already treated with AV and vice versa.
In conclusion, the avidin modification by conjugation with an
average of seven mPEG chains raises the plasma half-life of AV to
a value similar to SA. Moreover, the immunogenicity ofAV can be
successfully reduced with concurrent low cross-reactivity with AV.
Furthermore, as already successfully verified for some enzymes
(Caliceti et al, 1994), we have begun to investigate the protection
of the avidin active binding sites during the conjugation step using
soluble and insoluble biotin derivatives. Preliminary results are
consistent with the feasibility of this approach, as the percentage
ofbiotin binding ofAV-mPEG-7 increased from 33% (see Table 2)
to approximately 60%.
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